Industry: Pharmaceuticals, Biotechnology
Paradigm Therapeutics was founded in 1999 and has established world class target identification and validation capabilities based on gene knock out technology and in vivo pharmacology. The acquisition of Amedis Pharmaceuticals in January 2005 added key medicinal chemistry skills. The combined company has focused on the identification of novel, small molecule tractable targets with defined therapeutic utility within key gene families such as G-protein coupled receptors (GPCRs), ion channels and ( www.paradigm-therapeutics.com )
Paradigm Therapeutics Ltd
162 Cambridge Science Park
Cambridge, CB4 0GP
United Kingdom
Tel: +44 1223 477910
Fax: +44 1223 477911